LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Akciju saraksts・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Slēgts

1.28 4.92

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.16

Max

1.29

Galvenie mērījumi
By Trading Economics
Ienākumi	17M -26M
EPS	-0.43
Peļņas marža	-2,190.837
Darbinieki	171
EBITDA	19M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+147.93% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.5M 94M
Iepriekšējā atvēršanas cena	-3.64
Iepriekšējā slēgšanas cena	1.28

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.43 / 1.6 Atbalsts un pretestība

Pliant Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. dec. 23:48 UTC

Galvenie tirgus virzītāji

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

2025. g. 8. dec. 23:44 UTC

Tirgus saruna

Perky Australian Dollar Looks to Extend Gains -- Market Talk

2025. g. 8. dec. 23:42 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

2025. g. 8. dec. 23:09 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

2025. g. 8. dec. 22:46 UTC

Tirgus saruna

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

2025. g. 8. dec. 22:01 UTC

Tirgus saruna

Miners Poised to Do Well in 2026 -- Market Talk

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

2025. g. 8. dec. 21:51 UTC

Tirgus saruna

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

2025. g. 8. dec. 21:36 UTC

Tirgus saruna

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

2025. g. 8. dec. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

2025. g. 8. dec. 21:12 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 21:08 UTC

Tirgus saruna

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

2025. g. 8. dec. 20:38 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

2025. g. 8. dec. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 20:18 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

2025. g. 8. dec. 20:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 8. dec. 20:06 UTC

Tirgus saruna

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

2025. g. 8. dec. 20:01 UTC

Tirgus saruna

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pliant Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

147.93% augšup

Prognoze 12 mēnešiem

Vidējais 3 USD 147.93%

Augstākais 4 USD

Zemākais 2 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pliant Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pliant Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.43 / 1.6Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.